sign in sign up
<<
Home , Alexion Pharmaceuticals

Biotechnology Fund SCHEDULE OF INVESTMENTS (Unaudited) March 31, 2021

Shares Value COMMON STOCKS† - 99.5% Biotechnology - 73.5% , Inc. 4,765 $ 1,185,580 , Inc. 13,728 887,241 , Inc.* 3,423 735,568 Illumina, Inc.* 1,851 710,895 Regeneron Pharmaceuticals, Inc.* 1,474 697,408 , Inc.* 5,216 683,035 , Inc.* 2,363 661,049 Corteva, Inc. 12,335 575,058 Alexion Pharmaceuticals, Inc.* 3,736 571,272 , Inc.* 3,467 481,428 Exact Sciences Corp.* 3,563 469,532 Corp.* 5,196 422,279 Bio-Rad Laboratories, Inc. — Class A* 713 407,244 , Inc.* 2,834 400,132 Guardant Health, Inc.* 2,611 398,569 CRISPR Therapeutics AG* 2,967 361,529 BioMarin Pharmaceutical, Inc.* 4,752 358,824 BioNTech SE ADR*,1 3,047 332,702 Novavax, Inc.* 1,807 327,627 BeiGene Ltd. ADR* 816 284,033 Mirati Therapeutics, Inc.* 1,654 283,330 Acceleron Pharma, Inc.* 2,087 283,018 Fate Therapeutics, Inc.* 3,238 266,973 United Therapeutics Corp.* 1,585 265,123 Pharmaceutical, Inc.* 2,316 263,700 TG Therapeutics, Inc.* 5,416 261,051 Exelixis, Inc.* 11,452 258,701 Arrowhead Pharmaceuticals, Inc.* 3,834 254,233 Twist Bioscience Corp.* 1,940 240,288 Blueprint Medicines Corp.* 2,374 230,824 Halozyme Therapeutics, Inc.* 5,510 229,712 , Inc.* 5,063 227,632 Emergent BioSolutions, Inc.* 2,409 223,820 Iovance Biotherapeutics, Inc.* 6,734 213,198 Sage Therapeutics, Inc.* 2,734 204,640 Biohaven Pharmaceutical Holding Company Ltd.* 2,925 199,924 Arena Pharmaceuticals, Inc.* 2,820 195,680 ACADIA Pharmaceuticals, Inc.* 7,541 194,558 ChemoCentryx, Inc.* 3,536 181,185 PTC Therapeutics, Inc.* 3,489 165,204 Editas Medicine, Inc.* 3,869 162,498 Amicus Therapeutics, Inc.* 15,811 156,213 Global Blood Therapeutics, Inc.* 3,729 151,957 Bluebird Bio, Inc.* 4,616 139,172 Inovio Pharmaceuticals, Inc.*,1 14,239 132,138 Total Biotechnology 16,335,777 Pharmaceuticals - 17.1% AbbVie, Inc. 12,788 1,383,917 plc* 4,943 454,954 , Inc.* 28,197 393,912 PRA Health Sciences, Inc.* 2,049 314,173 Neurocrine Biosciences, Inc.* 3,171 308,380 plc* 1,865 306,550 Intellia Therapeutics, Inc.* 3,238 259,866 , Inc.* 3,031 225,900 Pacira BioSciences, Inc.* 2,463 172,632 Total Pharmaceuticals 3,820,284 Healthcare-Products - 5.4% Bio-Techne Corp. 998 381,166 Novocure Ltd.* 2,316 306,129 Natera, Inc.* 2,900 294,466 Adaptive Biotechnologies Corp.* 5,665 228,073 Total Healthcare-Products 1,209,834 Healthcare-Services - 3.5% Syneos Health, Inc.* 3,609 273,743 Invitae Corp.*,1 6,901 263,687 Medpace Holdings, Inc.* 1,460 239,513 Total Healthcare-Services 776,943 Total Common Stocks (Cost $11,322,919) 22,142,838

RIGHTS††† - 0.0% Biotechnology - 0.0% Clinical Data, Inc.* 4,730 – Total Rights (Cost $–) –

Face Amount REPURCHASE AGREEMENTS††,2 - 0.7% J.P. Morgan Securities LLC issued 03/31/21 at 0.01% due 04/01/21 $ 77,371 77,371 Barclays Capital, Inc. issued 03/31/21 at 0.01% due 04/01/21 35,176 35,176 BofA Securities, Inc. issued 03/31/21 at 0.01% due 04/01/21 32,104 32,104 Total Repurchase Agreements (Cost $144,651) 144,651

Shares SECURITIES LENDING COLLATERAL†,3 - 2.4% Money Market Fund First American Government Obligations Fund — Class Z, 0.03%4 524,211 524,211 Total Securities Lending Collateral (Cost $524,211) 524,211 Total Investments - 102.6% (Cost $11,991,781) $ 22,811,700 Other Assets & Liabilities, net - (2.6)% (588,128) Total Net Assets - 100.0% $ 22,223,572

* Non-income producing security. † Value determined based on Level 1 inputs. †† Value determined based on Level 2 inputs. ††† Value determined based on Level 3 inputs. 1 All or a portion of this security is on loan at March 31, 2021. 2 Repurchase Agreements. 3 Securities lending collateral. 4 Rate indicated is the 7-day yield as of March 31, 2021.

ADR — American Depositary Receipt plc — Public Limited Company